Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Compound Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Compound Therapeutics has engineered proteins, called Adzymes, which bind to targets with the specificity of antibodies but unlike them destroy their targets using an attached enzyme.

You may also be interested in...



Ambrx Inc.

Ambrx is using its technology for engineering proteins with novel amino acids--beyond the 20 that oocur in nature--to enhance the properties of proteins whose potential therapeutic uses, as well as liabilities, are known.

The Talent Challenge in Biologics Manufacturing

While companies are working hard to create new manufacturing capacity for biologics, protein production, which requires more highly trained and experienced workers, will remain constrained by a lack of qualified staff. Companies will need to act on a variety of fronts to deal with the problem--among them, more co-op hiring, and more partnering with companies with the requisite manufacturing capacity.

EngeneOS Inc.

Boston-area start-up engeneOS Inc. aspires to build molecular machines with starting materials that come from nature. The firm aims to take advantage of the the fact that proteins and nucleic acids have evolved highly specific capabilities over thousands of years. Management sees them as components that can be catalogued, combined and harnessed to carry out new tasks.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC090682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel